Gary Wild

10.6k total citations · 4 hit papers
144 papers, 7.7k citations indexed

About

Gary Wild is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Gary Wild has authored 144 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Genetics, 57 papers in Epidemiology and 48 papers in Surgery. Recurrent topics in Gary Wild's work include Inflammatory Bowel Disease (72 papers), Microscopic Colitis (46 papers) and Helicobacter pylori-related gastroenterology studies (23 papers). Gary Wild is often cited by papers focused on Inflammatory Bowel Disease (72 papers), Microscopic Colitis (46 papers) and Helicobacter pylori-related gastroenterology studies (23 papers). Gary Wild collaborates with scholars based in Canada, Hungary and United States. Gary Wild's co-authors include Richard N. Fedorak, Brian G. Feagan, Gordon R. Greenberg, John WD McDonald, Stephen B. Hanauer, Paul Rutgeerts, A. Hillary Steinhart, Alain Bitton, A. B. R. Thomson and Albert Cohen and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Gary Wild

135 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

2004 1.6k citations Bruce E. Sands, Frank Anderson et al. New England Journal of Medicine profile →
Methotrexate for the Treatment of Crohn's Disease

1995 651 citations Brian G. Feagan, Richard N. Fedorak et al. New England Journal of Medicine profile →
Treatment of Ulcerative Colitis with a Humanized Antibody to the α ₄ β ₇ Integrin

2005 535 citations Brian G. Feagan, Gordon R. Greenberg et al. New England Journal of Medicine profile →
A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease

2000 530 citations Brian G. Feagan, Richard N. Fedorak et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Gary Wild

Since Specialization

Citations

This map shows the geographic impact of Gary Wild's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Wild with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Wild more than expected).

Fields of papers citing papers by Gary Wild

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Wild. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Wild. The network helps show where Gary Wild may publish in the future.

Co-authorship network of co-authors of Gary Wild

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Wild. A scholar is included among the top collaborators of Gary Wild based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Wild. Gary Wild is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis 2025 ·Inflammatory Bowel Diseases ·(unknown), Péter L. Lakatos, (unknown), Victoria Marcus, Waqqas Afif, Gary Wild, Alain Bitton, Cristina Flores, Carlos Fernando de Magalhães Francesconi, Talat Bessissow	0
2	P0595 Comparative effectiveness between ustekinumab and vedolizumab after anti-TNF failure in Ulcerative Colitis: Real-world experience 2025 ·Journal of Crohn s and Colitis ·(unknown), (unknown), (unknown), (unknown), Virginia Solitano, (unknown), (unknown), (unknown), Gary Wild, Péter L. Lakatos, Neeraj Narula, Vipul Jairath, Talat Bessissow	0
3	P716 Efficacy and safety of upadacitinib during induction in Crohn’s disease: Real-world experience 2024 ·Journal of Crohn s and Colitis ·(unknown), (unknown), (unknown), Waqqas Afif, Alain Bitton, Gary Wild, Neeraj Narula, Péter L. Lakatos, Talat Bessissow	1
4	Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study 2023 ·The Turkish Journal of Gastroenterology ·Panu Wetwittayakhlang, Christine Verdon, Michael Starr, (unknown), Petra A. Golovics, Talat Bessissow, Waqqas Afif, Gary Wild, Alain Bitton, Péter L. Lakatos	1
5	Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study 2023 ·Digestive and Liver Disease ·Panu Wetwittayakhlang, (unknown), (unknown), (unknown), (unknown), Waqqas Afif, Gary Wild, Alain Bitton, Talat Bessissow, Péter L. Lakatos	10
6	Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases 2023 ·Crohn s & Colitis 360 ·(unknown), (unknown), (unknown), Sophie Restellini, Alain Bitton, Gary Wild, Waqqas Afif, Péter L. Lakatos, Talat Bessissow, Giada Sebastiani	4
7	Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study 2022 ·Journal of Gastrointestinal and Liver Diseases ·Panu Wetwittayakhlang, Petra A. Golovics, Alex Al Khoury, (unknown), (unknown), (unknown), Jonathan Wyse, Marc Bradette, Talat Bessissow, Waqqas Afif, Gary Wild, Alain Bitton, Péter L. Lakatos	2
8	P364 Patient reported outcomes, partial MAYO score and SCCAI are equally accurate in predicting mucosal healing in UC: final results form a prospective study 2021 ·Journal of Crohn s and Colitis ·Petra A. Golovics, Lóránt Gönczi, (unknown), Christine Verdon, Sheetal Pundir, Waqqas Afif, Gary Wild, Alain Bitton, Talat Bessissow, Péter L. Lakatos	0
9	Clinical Outcomes of COVID‐19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease 2021 ·Canadian Journal of Gastroenterology and Hepatology ·Panu Wetwittayakhlang, (unknown), Petra A. Golovics, (unknown), Talat Bessissow, Alain Bitton, Waqqas Afif, Gary Wild, Péter L. Lakatos	17
10	Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes 2020 ·World Journal of Gastroenterology ·(unknown), Lóránt Gönczi, Zsuzsanna Kürti, Isabelle Morin, (unknown), Christine Verdon, Jason Reinglas, Rita Kohen, Talat Bessissow, Waqqas Afif, Gary Wild, Ernest G. Seidman, Alain Bitton, Péter L. Lakatos	10
11	The Burden of Anemia Remains Significant over Time in Patients with Inflammatory Bowel Diseases at a Tertiary Referral Center 2020 ·Journal of Gastrointestinal and Liver Diseases ·Alex Al Khoury, (unknown), Zsuzsanna Kürti, Lóránt Gönczi, Petra A. Golovics, Rita Kohen, Waqqas Afif, Gary Wild, Alain Bitton, Talat Bessissow, Péter L. Lakatos	5
12	Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center 2019 ·Digestive Diseases and Sciences ·Jason Reinglas, Lóránt Gönczi, Christine Verdon, Talat Bessissow, Waqqas Afif, Gary Wild, Ernest G. Seidman, Alain Bitton, Péter L. Lakatos	12
13	Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF 2008 ·Pediatric Diabetes ·Terry Segal, (unknown), Russell Viner, Charles D. Pusey, Gary Wild, Jeremy Allgrove	25
14	Dietary Lipids Alter the Effect of Steroids on the Transport of Fructose Following Intestinal Resection in Rats 2008 ·Digestive Diseases and Sciences ·Aducio Thiesen, Kelly A. Tappenden, Michael I. McBurney, M. T. Clandinin, M. Keelan, A. B. R. Thomson, Laurie Drozdowski, Gary Wild	0
15	Infliximab Maintenance Therapy for Fistulizing Crohn's Disease breakdown → 2004 ·New England Journal of Medicine ·Bruce E. Sands, Frank Anderson, Çharles N. Bernstein, William Y. Chey, Brian G. Feagan, Richard N. Fedorak, Michael A. Kamm, Joshua R. Korzenik, Bret A. Lashner, Jane E. Onken, Daniel Rachmilewitz, Paul Rutgeerts, Gary Wild, Douglas C. Wolf, P Marsters, Suzanne Travers, Marion Blank, S J van Deventer	1607
16	A RANDOMIZED CONTROLLED TRIAL OF A HUMANIZED ALPHA4BETA7 ANTIBODY IN ULCERATIVE COLITIS (UC) 2003 ·The American Journal of Gastroenterology ·Brian G. Feagan, Gordon R. Greenberg, Gary Wild, John F. McDonald, Richard N. Fedorak, Pierre Paré, (unknown), (unknown), Julie Krop, Margaret K. Vandervoort	4
17	REVIEW: Small Bowel Review: Normal Physiology, Part 2 2003 ·Digestive Diseases and Sciences ·A. B. R. Thomson, Laurie Drozdowski, (unknown), Séverine Vermeire, M. T. Clandinin, Gary Wild	10
18	REVIEW: Small Bowel Review: Diseases of the Small Intestine 2001 ·Digestive Diseases and Sciences ·A. B. R. Thomson, M. Keelan, Aducio Thiesen, M. T. Clandinin, Mark J. Ropeleski, Gary Wild	36
19	Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease 2000 ·Gastroenterology ·Richard N. Fedorak, Alfred Gangl, Charles O. Elson, Paul Rutgeerts, Stefan Schreiber, Gary Wild, Stephen B. Hanauer, (unknown), Marielle Cohard, Alexandre LeBeaut, Brian G. Feagan	386
20	Controlled Trial of 4-ASA in Ulcerative Colitis 1997 ·Digestive Diseases and Sciences ·Warren L. Beeken, Diantha B. Howard, James C. Bigelow, Thomas D. Trainer, (unknown), Walter Thayer, Gary Wild	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact